COMPASS PATHWAYS PLC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
COMPASS PATHWAYS PLC (CMPS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.48 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-24
- 2021-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month 25.29 GBP/shares.
- 2020-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month 8.19 GBP/shares.
GBP/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month |
|---|---|
| 2021-06-30 | 25.29 GBP/shares 6-K · filed 2021-08-11 |
| 2020-06-30 | 8.19 GBP/shares 6-K · filed 2021-08-11 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.48 10-K · filed 2026-03-24 | |||
| 2024-12-31 | $7.00 10-K · filed 2026-03-24 | |||
| 2024-03-31 | $8.03 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $7.70 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $7.85 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $7.92 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $8.27 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $10.00 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $10.29 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | $10.67 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $11.38 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $21.35 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $22.71 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $25.29 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $26.73 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $9.83 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $8.25 6-K · filed 2021-11-09 | |||
| 2019-12-31 | $1.88 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |